Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer

NCT06467357 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06467357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06467357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
August 12, 2024
Completion date
May 16, 2029
Enrollment
620 (estimated)
Sites
272

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer